Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea

Lee, Dong Hun; Ko, Hyun Chang; Na, Chan Ho; Roh, Joo Young; Park, Kui Young; Park, Young Lip; Park, Young Min; Park, Chang Ook; Park, Chun Wook; Bae, Youin; Seo, Young‐Joon; Son, Sang Wook; Ahn, Jong Woong; Jung, Hye Jung; Yang, Jun-Mo; Won, Chong Hyun; Yoo, Kwang Ho; Lew, Bark Lynn; Lee, Sangeun; Lee, Sung Yul; Lee, Seung-Chul; Lee, Yang Won; Lee, Ji Hyun; Jang, Yo-Soon; Jeon, Jiehyun; Han, Tae Young; Cho, Sang Hyun

doi:10.5021/ad.2022.34.2.157

Cited by 5 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dupilumab is a monoclonal antibody that targets the alpha subunit of the interleukin (IL)-13 receptor which has shown significant efficacy in patients with moderate-to-severe AD 1 . The current understanding and recommendations for COVID-19 show no indication that AD is a risk factor to alter the vaccination schedule, and its potential to cause AD flare-up is unclear 2 3 , while dupilumab is also not expected to cause vaccine attenuation 4 .…”

Section: Introductionmentioning

confidence: 99%

Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Atopic dermatitis (AD) patients usually wonder if their condition will worsen after vaccination or if they should continue with the treatment they are receiving. Considering that many patients treated with dupilumab had previously experienced severe AD symptoms and flares, the concerns are more understandable. Objective This study aimed to investigate the safety of the coronavirus disease 2019 (COVID-19) vaccination in patients with AD treated with dupilumab. Methods We enrolled 133 patients (101 dupilumab-treated and 32 systemic oral agents-treated as control group) with AD from six hospitals. Patients were asked about worsening pruritus and AD (5-point Likert scale) after vaccination. AD variables (eczema area and severity index [EASI], investigator’s global assessment [IGA], itch numerical rating scale [NRS], sleep NRS, and patient-oriented eczema measure [POEM]) were compared pre- and post-vaccination. Adverse reactions to the COVID-19 vaccination were observed. Results The incidence of adverse reactions to COVID-19 vaccines and worsening AD symptoms in dupilumab-treated patients were not significantly different compared with that in the control group. The itch NRS score increased significantly after vaccination ( p <0.001). However, there were no statistically significant differences between the pre-and post-EASI, IGA, and POEM scores. Eight patients (7.9%) had worse EASI scores and required rescue therapy; however, most were easily managed with low-dose steroids or topical agents. None of the patients discontinued dupilumab treatment. Conclusion No serious adverse reactions were observed in patients with AD after COVID-19 vaccination. Exacerbation of pruritus and AD symptoms was observed but was mostly mild and transient.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinical studies have shown optimistic efficacy of Dupilumab, while some studies found that Dupilumab could induce an increase in blood eosinophils. 3 Clinicians may be concerned about whether changes in eosinophils may limit the continued use of Dupilumab. 4 In this study, we evaluated the changes in eosinophil counts after Dupilumab treatment through meta-analysis.…”

mentioning

confidence: 99%

The changes of eosinophil counts in patients after treatment of Dupilumab: A systematic review and meta‐analysis

Zhou

Liang

Shang

et al. 2022

Allergy

View full text Add to dashboard Cite

To the Editor, The type 2 immune response is mediated by Th2 and ILC2s cells, through the production of type 2 cytokines such as IL-4, IL-13, and IL-5. Multiple cells, including eosinophils, are active by these cytokines. In healthy individuals, eosinophils account for 1%-5% of peripheral blood leukocytes. The type 2 inflammatory diseases include a series of allergic, immune diseases, such as atopic dermatitis, asthma, allergic rhinitis and eosinophilic esophagitis. 1,2 Dupilumab is a fully human monoclonal antibody, which blocks IL-4/13. Clinical studies have shown optimistic efficacy of Dupilumab, while some studies found that Dupilumab could induce an increase in blood eosinophils. 3 Clinicians may be concerned about whether changes in eosinophils may limit the continued use of Dupilumab. 4 In this study, we evaluated the changes in eosinophil counts after Dupilumab treatment through meta-analysis. Data from different studies were merged, and at different weeks, comprehensive results were obtained.We searched five databases up to December 31, 2021, to select eligible publications. For included studies, quality was assessed.For randomized studies, the risk of bias tool was applied. For observational studies, Newcastle-Ottawa Scale was applied. The standardized mean difference (SMD) was used to evaluate the change.According to the between-study heterogeneity, fixed or random effect model was selected. The detail of selection and study quality were in Figure S1.Ten studies were included. Three diseases were included and analyzed through meta-analysis. The detail was in Table 1. At weeks 8, 16, 48, 100, and 148, eosinophil counts showed significant decrease (P < .05), which were SMD = −0.18 (95%CI: −0.31, −0.05); −0.17

show abstract

Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis

Han

Koh

Hong

et al. 2023

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea

Cited by 5 publications

References 9 publications

Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study

Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study

The changes of eosinophil counts in patients after treatment of Dupilumab: A systematic review and meta‐analysis

Adipose-derived stem cell exosomes for treatment of dupilumab-related facial redness in patients with atopic dermatitis

Contact Info

Product

Resources

About